Business
Astellas to Present New Clinical Data Across Its Gastrointestinal Cancers Portfolio at 2026 ASCO GI Cancers Symposium
Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced it will present data on potential treatments for pancreatic and gastric/gastroesophageal junction (G/GEJ) cancer at the 2026 American Society of Clinical Oncology (ASCO) Gastrointestinal (GI) Cancers Symposium taking place January 8-10, 2026 in San Francisco, California. Highlights include a late-breaking oral presentation of cohort results from the Phase 2 ILUSTRO study of first-line zolbetuximab in c
About this update from Astellas Pharma Inc.
[{"type":"text","content":"- Data reflect new insights and precision oncology advancements in portfolio and pipeline -","length":91,"tagName":"p","attribs":{}},{"type":"text","content":"- Cohort results from Phase 2 ILUSTRO study evaluating a zolbetuximab triplet combination regimen in first-line advanced gastric and gastroesophageal junction (GEJ) cancer featured in late-breaking oral presentation -","length":217,"tagName":"p","attribs":{}},{"type":"text","content":"TOKYO, Dec. 10, 2025 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced it will present data on potential treatments for pancreatic and gastric/gastroesophageal junction (G/GEJ) cancer at the 2026 American Society of Clinical Oncology (ASCO) Gastrointestinal (GI) Cancers Symposium taking place January 8-10, 2026 in San Francisco, California. Highlights include a late-breaking oral presentation of cohort results from the Phase 2 ILUSTRO study of first-line zolbetuximab in combination with chemotherapy and immunotherapy in claudin 18.2-positive, HER2-negative, locally advanced or metastatic G/GEJ cancer, as well as new Phase 1 data from ASP3082 (setidegrasib), an investigational KRAS G12D targeted protein degrader, in pancreatic cancer.","length":824,"tagName":"p"},{"type":"image","alt":"Astellas stands on the forefront of healthcare change to turn innovative science into value for patients.(PRNewsFoto/Astellas Pharma Inc.) (PRNewsfoto/Astellas Pharma Inc.)","displaySize":"","headline":null,"caption":"Astellas stands on the forefront of healthcare change to turn innovative science into value for patients.(PRNewsFoto/Astellas Pharma Inc.) (PRNewsfoto/Astellas Pharma Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":110,"url":"https://media.zenfs.com/en/prnewswire.com/2ea847d4f0afcbab05cc0666e5cfd53b"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/gt2H1Ajgjzgw_owZJZe3uA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTE5NDtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/2ea847d4f0afcbab05cc0666e5cfd53b","width":400,"height":110}},"href":"https://mma.prnewswire.com/media/458529/Astellas_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Moitreyee Chatterjee-Kishore, Ph.D., M.B.A., Head of Oncology Development, Astellas"At Astellas, we are harnessing nex...